博騰股份(300363.SZ)連續第三日漲停 為吉利德的瑞德西韋提供CDMO服務
格隆匯2月5日丨繼前兩個交易日漲停後,博騰股份(300363.SZ)今日再度一字漲停,報20.98元,目前漲停封單多達近50萬手,暫成交1939萬元,最新總市值114億元。公司昨晚公告:“公司於2015年開始為吉利德科學在研抗病毒藥物Remdesivir(瑞德西韋)提供定製研發生產(CDMO)服務,並於2016年多次交付臨牀需求的高級中間體。近日,公司已收到吉利德科學關於相關抗病毒藥物中間體的正式業務詢,目前公司正在積極與吉利德科學商洽,並做好了全方位的保障和準備”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.